

Robarts Translational Research Consortium

presents the second annual symposium on

Leukocyte Trafficking: Applying Precision Medicine to IBD

February 12, 2020

Vienna, Austria

at Courtyard by Marriott Vienna,
Prater/Messe
4 Trabrennstrabe,
Vienna, 1020

This Symposium is supported by Arena Pharmaceuticals and Celgene

CONNECT

robartsclinincaltrials.com

Symposium on Leukocyte Trafficking: Applying Precision Medicine to IBD

Agenda for February 12, 2020

7:45 AM	Registration & Continental Breakfast
8:15 AM	Welcome & Introductions of the Robarts Translational Research Consortium
	Session 1: Clinical Efficacy & Safety
8:45 AM	State of the art: strategies to modulate leukocyte trafficking Dr. Jesus Rivera-Nieves – UC San Diego, USA
9:10 AM	Safety and Efficacy of anti-integrins Dr. Brian Feagan – Western University / Robarts Clinical Trials, Canada
9:35 AM	Safety and Efficacy of S1P modulators Dr. William Sandborn – UC San Diego, USA
10:00 AM 10:15 AM	Panel discussion Break
	Session 2: Clinical Pharmacology & Translational Medicine
10:30 AM	Predictors for response, treatment intensification, and/or discontinuation Dr. Severine Vermeire – KU Leuven, Belgium
10:55 AM	Impact of migration inhibitors on the mucosal and systemic immune system Dr. Saurabh Mehandru – Mount Sinai - New York, USA
11:20 AM	Pharmacokinetics & pharmacodynamics of anti-trafficking agents Dr. Niels Vande Casteele – UC San Diego / Robarts Clinical Trials, USA
11:45 AM	Panel Discussion
Noon	Lunch

Session 3: Drug Design & Development 1:00 PM Combination therapy redefined Dr. William Faubion - Mayo Clinic - Rochester, USA 1:25 PM Overview of the pipeline and strategies for efficient drug development Dr. Arthur Kaser – University of Cambridge, UK 1:50 PM Panel discussion **Session 4: Breakout Session** Update Since 2019 Symposium and Introduction of PROPHETIC Study 2:20 PM Dr. Niels Vande Casteele – UC San Diego / Robarts Clinical Trials, USA 2:40 PM Break 3:00 PM Working groups to identify areas of translational research that can guide treatment strategies and accelerate further drug development 4:00 PM Working group presentation & general discussion 5:00 PM Summary of proposed objectives 5:10 PM Adjourn

- Reception to follow -